US genetic testing company Illumina announced that it will make a goodwill impairment expense of $1.47 billion in the second quarter, which is related to the recently divested cancer diagnostic test manufacturer Grail, and may result in about $420 million additional impairment charges for Grail's in-progress research and development intangible assets (IPR&D) recognition. However, the company added that there are no significant cash outflows expected in the future related to these impairments.
Illumina将在Q2计提与Grail相关的14.7亿美元商誉减值支出
Illumina will make a $1.47 billion goodwill write-down related to Grail in Q2.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.